Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $274000.0.

  • Rhythm Pharmaceuticals' Non Operating Income fell 7481.62% to $274000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 13193.31%. This contributed to the annual value of $5.2 million for FY2024, which is 205925.93% up from last year.
  • Rhythm Pharmaceuticals' Non Operating Income amounted to $274000.0 in Q3 2025, which was down 7481.62% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Non Operating Income peaked at $100.2 million during Q1 2021, and registered a low of -$2.4 million during Q1 2025.
  • Moreover, its 5-year median value for Non Operating Income was -$99000.0 (2023), whereas its average is $5.5 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Non Operating Income tumbled by 125507.25% in 2022 and then soared by 888383.84% in 2024.
  • Rhythm Pharmaceuticals' Non Operating Income (Quarter) stood at $134000.0 in 2021, then crashed by 391.04% to -$390000.0 in 2022, then soared by 55.9% to -$172000.0 in 2023, then crashed by 1136.63% to -$2.1 million in 2024, then soared by 112.88% to $274000.0 in 2025.
  • Its Non Operating Income was $274000.0 in Q3 2025, compared to $1.6 million in Q2 2025 and -$2.4 million in Q1 2025.